Illinois Considers Prescription Drug Affordability Panel Amidst Debates
In Springfield, Illinois lawmakers are nearing the end of their spring legislative session with 11 days left. They are debating a proposal to establish a state panel aimed at reviewing prescription drug prices and addressing concerns about drug accessibility. This initiative to create a Prescription Drug Affordability Board is part of a larger effort by Democrats to tackle what they describe as an affordability crisis affecting not only Illinois but the entire nation.
Critics of the measure argue that while the board may add layers of bureaucracy, it may not effectively reduce prices. The bill passed through the House Executive Committee with an 8-4 vote along party lines and is now awaiting a full House vote. Advocates view the board as a mechanism to control escalating drug costs, a subject also being tackled nationally under recent federal initiatives.
State Representative Nabeela Syed of Palatine, a primary sponsor of the bill, described it as the result of significant negotiation. The proposal includes the creation of a five-member board appointed by the governor. This board would have the power to evaluate most drug costs, determine if prices are excessive, and set caps on what consumers pay. Pharmaceutical companies would be allowed to justify their pricing before any caps are implemented. The board’s duties would also include enhancing medication access, especially in underserved rural and low-income communities.
A significant part of this legislation ties Illinois drug prices to Medicare’s newfound negotiation capabilities under the 2022 Inflation Reduction Act. Starting this year, Medicare began negotiating lower prices for ten high-cost medications. For instance, a 30-day supply of Januvia, a diabetes drug, decreased from $527 to $113, and Enbrel, used for rheumatoid arthritis, dropped from $7,106 to $2,355, based on information from the Centers for Medicare & Medicaid Services.
Under the proposed bill, these Medicare-negotiated prices would automatically set the upper payment limits for Illinois consumers across various health plans. However, Medicaid and certain state employee health programs would need separate opting-in processes. While the board couldn’t further reduce prices for drugs already negotiated by Medicare, it could help ensure these drugs are accessible to those in need.
Anusha Thotakura, executive director of Citizen Action/Illinois which supports the bill, referenced an April study indicating that Illinois overpays by over $190 million for drugs impacted by Medicare’s rates. Though opponents have questioned this figure, Thotakura insists it highlights substantial overspending.
The legislation specifies that board members must have expertise in healthcare, pharmacy, or clinical medicine, yet they cannot work for or have ties to drug manufacturers. Members would hold five-year terms, with the initial appointments staggered. Additionally, a 15-member advisory council would support the board, with appointments by the governor, House speaker, Senate president, and minority leaders. Board decisions can be appealed and subjected to judicial review.
Across the U.S., around a dozen states have active Prescription Drug Affordability Boards (PDABs), but with varying scopes. In states like Maryland, Colorado, and Minnesota, boards can set upper payment limits for drugs. However, the Pharmaceutical Research and Manufacturers of America expressed dissatisfaction, stating no active boards have yet delivered notable savings. They argue the federal Medicare pricing framework was never meant for state-level application.
Deputy Republican leader Ryan Spain from Peoria voiced concerns about the legislative framework, highlighting a lack of a state agency to manage the board and criticizing the potential complexity it would introduce. Syed maintains the board functions independently, estimating operational costs at $750,000 and seeing no necessity for it to fall under any state department.
Regarding governance, spokespersons for Democratic Governor JB Pritzker have not disclosed his stance on the board, saying the proposal is under review. Concurrently, the legislature approved another bill, promoted by Pritzker, banning “junk fees” and requiring transparent pricing in advertisements, which now awaits the governor’s signature after passing the Senate.